Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2021 version (5th JSH‐HCC Guidelines)
Kiyoshi Hasegawa(The University of Tokyo), Ryosuke Tateishi(The University of Tokyo), Nobuyuki Takemura(National Center for Global Health and Medicine), Takuji Torimura(Kurume University), Kaoru Tsuchiya(Musashino Red Cross Hospital), Masafumi Ikeda(National Cancer Center Hospital East), Satoshi Kobayashi(Kanazawa University), Masatoshi Kudo(Kindai University), Utaroh Motosugi(Iwaki Kyoritsu General Hospital), Hiroshi Aikata(Hiroshima University), Shoji Kubo(Osaka Metropolitan University), Masaki Kaibori(Kansai Medical University), Etsuro Hatano(Kyoto University), Junji Furuse(Kyorin University), Masaaki Akahane(International University of Health and Welfare), Hiroko Iijima(Hyogo University), Mitsuo Shimada(Tokushima University), Kazuyoshi Ohkawa(Osaka International Cancer Institute), Takuya Genda(Juntendo University Shizuoka Hospital), Takeyuki Watadani(The University of Tokyo), Kazuomi Ueshima(Kindai University), Tatsuya Yamashita(Kanazawa University), Hideyuki Sakurai(University of Tsukuba), Yutaka Matsuyama(The University of Tokyo), Takamichi Murakami(Kobe University), Hiroaki Nagano(Yamaguchi University), Atsuya Takeda(Gunma Chuo Hospital)
Cited by 267
Related Papers
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
|NEJM Evidence|2022|1.1k